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Large-scale genetic analyses of human tumor samples
have been used to identify novel oncogenes, tumor
suppressors and prognostic factors, but the functions and
molecular interactions of many individual genes have not
been determined. In this study we examined the cellular
effects and molecular mechanism of the arrestin family
member, ARRDC3, a gene preferentially lost in a subset
of breast cancers. Oncomine data revealed that the
expression of ARRDC3 decreases with tumor grade,
metastases and recurrences. ARRDC3 overexpression
represses cancer cell proliferation, migration, invasion,
growth in soft agar and in vivo tumorigenicity, whereas
downregulation of ARRCD3 has the opposite effects.
Mechanistic studies showed that ARRDC3 functions in a
novel regulatory pathway that controls the cell surface
adhesion molecule, b-4 integrin (ITGb4), a protein
associated with aggressive tumor behavior. Our data
indicates ARRDC3 directly binds to a phosphorylated
form of ITGb4 leading to its internalization, ubiquitina-
tion and ultimate degradation. The results identify the
ARRCD3-ITGb4 pathway as a new therapeutic target in
breast cancer and show the importance of connecting
genetic arrays with mechanistic studies in the search for
new treatments.
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Introduction
The basal-like subset of breast cancer was ﬁrst identiﬁed
as tumors lacking hormone receptor and human
epidermal growth factor receptor 2 ampliﬁcation with
a gene expression proﬁle similar to basal or myoepithe-
lial cells of the breast (Perou et al., 2000). Basal-like
breast cancers account for 8–37% of all breast cancers
(depending on the deﬁnition criteria) and is associated
with a poor prognosis; increased development of distant
metastasis, decreased survival rate and increased mor-
tality (reviewed in (Rakha et al., 2008; Voduc and
Nielsen, 2008; Rakha and Ellis, 2009)). As these tumors
lack the expression of estrogen and progesterone
receptors as well as human epidermal growth factor
receptor 2, there are limited options that are largely
ineffective in treating patients suffering from basal-like
breast cancer.
Large-scale genetic analyses of human tumor samples
have generated a wealth of molecular information and
have identiﬁed potential tumor suppressors, oncogenes
and prognostic factors (Perou et al., 2000; Srlie et al.,
2001; Sotiriou and Pusztai, 2009). The challenge now is
to study the function of these new genes and understand
their mechanisms of action to validate their clinical
utility and conﬁrm their potential use as targets of
intervention. The arrestin family member ARRDC3 is
one such gene that was recently found within a cluster
on chromosome 5 deleted in 17% of basal-like breast
cancers (compared with 0% in luminal breast-cancers)
suggesting a role as a tumor suppressor (Adelaide et al.,
2007). ARRDC3 contains structural homology to the
arrestin family of proteins, which has an important
role in the internalization and subsequent regulation of
G protein-coupled receptors (GPCRs). Although
ARRDC3 has been classiﬁed as an a-arrestin, there is
a cluster of acidic and hydrophobic residues that may
bind to clathrin, suggesting a role in membrane protein
internalization (Alvarez, 2008). This is further supported
by the putative structural homology between ARRDC3
and other arrestin family members VPS26 and b-arrestin
(Aubry et al., 2009). A role for ARRDC3 connecting the
PPARg signal and endosomal functions has been
suggested (Oka et al., 2006).
Integrins (ITGs) are cell surface adhesion molecules
which mediate cell–extracellular matrix and cell–cell
interactions. Binding of ITGs to their ligands initiates
several signaling events that modulate many cellular
behaviors, such as adhesion, proliferation, survival,
motility, gene expression and differentiation (Dowling
et al., 1996; Fuchs et al., 1997; Hynes, 2002; Watt, 2002;
Arnaout et al., 2005; Lipscomb et al., 2005; Wilhelmsen
et al., 2006; Germain et al., 2009; Vicente-Manzanares
et al., 2009). The ITGb4 subunit was initially identiﬁed
in cancer as a tumor-related antigen associated with
metastasis (Falcioni et al., 1989; Lee et al., 1992) and
was later found to promote motility and invasion in
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ITGb4 signaling increases invasive potential and has
been shown to sustain the survival of carcinoma cells in
stressful environments (Yoon et al., 2005; Baril et al.,
2007; Chen et al., 2009). Recent human studies have
found that ITGb4 expression is correlated to breast
cancer size and grade (Diaz et al., 2005), and signiﬁ-
cantly correlates with basal-like breast cancer (Lu et al.,
2008). ITGb4 expression is also linked to poor patient
prognosis in a variety of cancers (Raymond et al., 2007).
Despite its signiﬁcance in tumor progression, surpri-
singly little is known about the regulation of ITGb4a t
the protein level. It is phosphorylated during signal
transduction and thought to be internalized, trafﬁcked
around the cell, and either recycled or degraded
(Hemler, 2001; Caswell and Norman, 2006, 2008;
Wilhelmsen et al., 2007; Dutta and Shaw, 2008;
Germain et al., 2009). It has been hypothesized that
after hemidesmosome disrupting signals, newly liberated
ITGb4 is rendered capable for signaling. Activation
results in the release of ITGb4 from interactions with
the cytokeratin cytoskeleton and allows for de novo
interaction with the actin cytoskeleton and signaling
molecules (Rabinovitz and Mercurio, 1996; Yoon et al.,
2005; Mitra and Schlaepfer, 2006). However, little is
known about the mechanism for which this occurs.
To understand the function of ARRDC3 we used
overexpression and short hairpin RNA-mediated down-
regulation in human breast cancer cells. We showed
signiﬁcant effects on breast cancer cell migration and
growth that coincided with dramatic effects on the cell
surface protein ITGb4. In this study we showed that
ARRDC3 functions as a novel regulator of tumor
progression in breast cancer because of its effects on
ITGb4 internalization and degradation.
Results
ARRDC3 expression is downregulated during tumor
progression
To investigate how ARRDC3 expression is altered
during carcinogenesis, we used Oncomine to analyze
previously published microarray data. Levels of
ARRDC3 mRNA are lower in breast cancer tissues when
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Figure 1 Downregulation of ARRDC3 is an early event in carcinogenesis. Oncomine was used to analyze previously published
microarray data. (a) Levels of ARRDC3 mRNA are decreased in human breast cancers when compared with normal breast tissue.
(b) ARRDC3 mRNA levels decrease in human mammary epithelial cells after transformation with various oncogenes. (c) Levels of
ARRDC3 mRNA are decreased in metastatic lesions when compared with the primary tumor in the same patient. (d) Expression of
ARRDC3 mRNA is decreased in the initial ERþ tumors from patients that have relapsed when compared with 5-year disease-free
patients. All data, including P-values, were calculated from Oncomine.
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Oncogenecompared with normal tissue (Figure 1a). Furthermore,
ARRDC3 mRNA levels decrease on the transformation
of human mammary epithelial cells (Figure 1b). Onco-
mine data also revealed a decrease in ARRDC3 mRNA
in metastatic tumors when compared with the primary
tumor (Figure 1c). In addition, ARRDC3 levels are lower
in tumors of breast cancer patients that relapsed within 5
years of diagnosis when compared with patients that
remained disease free for 45 years (Figure 1d). Com-
bined, these data indicate that ARRDC3 repression
occurs early in carcinogenesis, decreases throughout
tumor progression and suggests that low ARRDC3
may indicate a poor prognosis.
ARRDC3 affects in vitro cancer cell tumorigenicity
To evaluate the potential role of ARRDC3 as a
suppressor of tumor growth, we generated stable cancer
cell lines either overexpressing or repressing ARRDC3
in the basal-like breast cancer cell line MDA-MB-231
cells. The MDA-MB-231 line was used because it is
considered a basal-like breast cancer cell line that had
detectable levels of ARRDC3 and ITGb4 when com-
pared with other cell lines (Supplementary Figure S1).
In Addition, MDA-MB-231 cells depend on ITGb4
signaling for cell adhesion, survival, migration and
invasion (Lipscomb et al., 2003, 2005). Expression of
ARRDC3 indicated that there was not a chromosomal 5
deletion therefore, we could manipulate levels to observe
effects on tumorigenicity.
We ﬁrst noticed a change in the comparative growth
rates. ARRDC3 overexpression causes a decrease in cell
growth rates, whereas the repression of ARRDC3
increases cell growth (Figure 2a). To investigate the
effects on invasiveness, sublines were used in a
chemoinvasion assay. Overexpression of ARRDC3
caused a 50% reduction in the number of invasive cells,
wheras repression of ARRDC3 caused a twofold
increase (Figure 2b). Sublines were then used in a
wound assay to test whether ARRDC3 affects cancer
cell migration. We found a dramatic decrease in
cell migration when ARRDC3 was overexpressed
(Figure 2c). Sublines with repressed ARRDC3 exhibited
a signiﬁcant increase in migration rate. We next
evaluated the importance of ARRDC3 for anchorage
independent growth by calculating the colony number
and size after 4-weeks growth in soft agar. There was a
signiﬁcant decrease in colony number in the ARRDC3
overexpressing sublines, whereas sublines with repressed
ARRDC3 showed a signiﬁcant increase in colony
number (Figure 2d). ARRDC3 expression also affected
the size of the colonies; sublines with repressed
ARRDC3 had a higher percentage of colonies larger
than 4200mm, whereas lines overexpressing ARRDC3
had a lower percentage of colonies 4200mm
(Figure 2e).
ARRDC3 suppresses in vivo tumorigenicity
To assess the role of ARRDC3 in tumor growth in vivo,
the stable subclones of MDA-MB-231 cells were injected
into the mammary fat pad of nude mice (n¼20 for
each subline). All subclones formed tumors efﬁciently in
85–100% of the mice suggesting that ARRDC3 does not
affect in vivo tumor incidence. However, sublines with
repressed ARRDC3 formed measurable tumors more
quickly (2 weeks) when compared with the control line
(3 weeks). In contrast, the formation of tumors from the
ARRDC3 overexpressing line was delayed (4 weeks)
when compared with the control line (3 weeks). After 7
weeks of injection, mice were killed and tumors were
dissected and measured. ARRDC3 signiﬁcantly sup-
pressed tumor growth in vivo as determined by the ﬁnal
tumor volume measurements (Figures 3a–c). All tumors
showed a similar undifferentiated solid tumor morpho-
logy (Supplementary Figure S2a). To determine whether
there was a difference in the proliferation, sections from
the xenograft tumors (n¼5 tumors for each cell line)
were stained for Ki67. As expected from the in vitro
studies, repressing ARRDC3 increases the percent of
Ki67 positive cells by almost twofold, whereas over-
expressing ARRDC3 decreases the number of Ki67-
positive cells by approximately threefold (Figure 3d and
Supplementary Figure S2b).
To assess the contribution of ARRDC3 to in vivo
tumor cell survival, sections of xenograft tumors
were evaluated for central necrosis. The areas of necrosis
and total tumor area were quantiﬁed using ImageJ
software (n¼4 tumors of each cell line). Although larger
tumors are generally more necrotic, tumors derived
from the shARRDC3 lines contained signiﬁcantly less
necrosis when compared with control tumors (Figures
4a and b). In contrast, tumors from the ARRDC3
overexpressing cell line, although smaller, were highly
necrotic (Figures 4a and b). Terminal deoxynucleotidyl
transferase-mediated dUTP-biotin nick end labeling
staining was also carried out on sections from the
xenograft tumors. The expression of ARRDC3 seemed
to have no effect on the number of apoptotic cells
(Figure 4c and Supplementary Figure S2c), suggesting
that ARRDC3 functions independently from the apop-
totic pathway.
Figure 2 Expression of ARRDC3 affects in vitro tumorigenicity Each line was tested in triplicate and data bars represent mean±s.e.m.
Single asterisk represents Po0.05, whereas a double asterisk represents Po0.001 as determined by Student’s t-test. (a) Growth curves
from the stable lines show that ARRDC3 overexpression suppresses cellular proliferation, whereas repression enhanced proliferation.
(b) Matrigel chemo-invasion assay show that ARRDC3 overexpression suppresses invasion, whereas repression enhances invasion.
(c) Wound assay of mitomycin-C treated cells shows that overexpression of ARRDC3 leads to a decrease in cell migration, whereas
RNA interference-mediated repression of ARRDC3 increases cell migration. (d) ARRDC3 overexpression suppresses anchorage
independent growth, whereas repression enhances anchorage independent growth. (e) Both colony number and colony size are affected.
Dark gray bars represent total colonies (at least 50mm), whereas light gray bars represent colonies larger than 200mm.
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OncogeneARRDC3 negatively regulates ITGb4
Initial studies using adenoviral vectors to overexpress
ARRDC3 gave approximately 40-fold increase in
protein and caused a complete detachment of MDA-
MB-231 cells from the substratum after 1 week in
culture suggesting a defect in cell adhesion. As cell
adhesion and tumorigenic properties of MDA-MB-231
cells are dependent on ITGb4, we hypothesized that
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OncogeneARRDC3 was affecting ITGb4 expression. To deter-
mine whether ARRDC3 expression inﬂuences ITGb4
levels in breast cancer cells, the stable lines with
approximately ﬁvefold ARRDC3 overexpression and
RNA interference knockdown were analyzed by western
blot. Overexpression of ARRDC3 caused a signiﬁcant
decrease in ITGb4 protein levels, whereas cells with
repressed ARRDC3 expression show a marked increase
in ITGb4 (Figure 5a). To verify ITGb4 was only
affected in cells with altered ARRDC3, cells were
infected with a green ﬂuorescent protein-expressing
ARRDC3 adenovirus and evaluated for ITGb4 levels
using immunoﬂuorescence. Cells that overexpress
ARRDC3 showed signiﬁcant downregulation of ITGb4
surface levels, whereras adjacent uninfected cells showed
no change in ITGb4 protein levels (Figure 5b). Addi-
tionally, a partial detachment of ARRDC3 overexpres-
sing cells from the substratum can be seen in culture
24h after infection (Figure 5b). As expected, ITGb4
expression and cell attachment were not affected by
infection with the control green ﬂuorescent protein
adenovirus. Flow cytometric analysis also showed that
overexpression of ARRDC3 causes an ablation of
ITGb4 protein from the cell surface (Figure 6c).
Interestingly, although ITGb4 is altered in our stable
MDA-231 cell lines (Figure 5a), these cells did not show
the loss of adhesion seen in adenoviral infected cells.
This is likely because of the higher expression levels that
can be achieved with adenovirus.
ARRDC3 regulates ITGb4 protein levels in a
proteosome-dependent manner
We next wanted to determine the mechanism of ITGb4
degradation in breast cancer cells. Parental MDA-MB-
231 cells were infected with adARRDC3 and then treated
with the proteosome inhibitor lactacystin for 6h. The
addition of 25mM lactacystin prevented the ARRDC3-
mediated decrease in ITGb4 protein levels as determined
by immunoﬂuorescence and western blots (Figures 6a and
b). Lactacystin treatment did not prevent internalization
of surface ITGb4, although a low level of ITGb4 was still
detectable on the surface (Figure 6c), suggesting that
undegraded protein can be recycled to the cell surface. To
exclude the possibility of lysosomal contribution to the
protein degradation, ARRDC3 overexpressing cells were
treated with the lysosomal inhibitor, chloroquine at 50mM
for 18h. Chloroquine treatment did not prevent ITGb4
reduction after infection with adARRDC3 (Supplemen-
tary Figures S3a and b).
As the regulation of ITGb4 by ARRDC3 seemed to
be dependent on the proteosome, and as to other
arrestin family members have a role in targeting
receptors for degradation (Gurevich and Gurevich,
2006; Bhandari et al., 2007; Kendall and Luttrell,
2009; Zhang et al., 2009), we asked whether ARRDC3
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Figure 3 ARRDC3 negatively regulates in vivo tumorgenicity. Stable
cells lines of MDA-MB-231 cells were injected into the mammary fat
pads of immunocompromised mice (n¼20 injections for each cell
line) and grown for 7 weeks. (a–b) Overexpression of ARRDC3
(ARRDC3) led to a decrease in in vivo tumor size compared with
vector control (Flag), whereas repression of ARRDC3 (shARRDC3)
led to an increase in tumor size compared with control (shCtl). (c)
When quantiﬁed, the differences in ﬁnal tumor volume were
statistically signiﬁcant compared with scrambled short hairpin RNA
and empty vector controls. (d) ARRDC3 affects the in vivo
proliferation of tumor cells as determined by percentage of Ki67-
positive cells. Xenograft tumor sections were analyzed for Ki67 using
IHC. Over 1500 cells per tumor were counted and scored either
Ki67þ or Ki67 . In all, four to ﬁve tumor samples per group were
analyzed and data bars represent mean±s.e.m. Single asterisk
represents Po0.05, whereas a double asterisk represents Po0.001
as determined by Student’s t-test.
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Oncogeneinteracts with ITGb4 after it is targeted for degradation.
Untreated MDA-MB-231 cells show an undetectable
amount of ubiquitinated ITGb4, even after immuno-
precipitation. However, when cells were pretreated with
proteosome inhibitor lactacystin, higher molecular
weight bands of ITGb4 were detected after immuno-
precipitation with both ARRDC3 and ITGb4 anti-
bodies (Figure 6d). Immunoblotting for Ubiquitin
revealed that almost equal amounts of ubiquitinated-
ITGb4 is coimmunoprecipitated with the ARRDC3
antibody when compared with the ITGb4 immunopre-
cipitation (Figure 6d). Thus, ARRDC3 binds ITGb4
after ubiquitination, and seems likely to have a role in
targeting ITGb4 for degradation.
ARRDC3 directly interacts with activated ITGb4
A novel phosphorylation site on ITGb4, serine-1424,
was recently identiﬁed as important in hemidesmosome
disassembly and was enriched on the trailing edge of
migrating cells (Germain et al., 2009). This phospho-
rylation, along with the phosphorylation of other
serines, results in the disassembly of the hemidesmosome
and mobilization of ITGb4 to actin-rich protrusions
(Rabinovitz et al., 2004; Wilhelmsen et al., 2007;
Germain et al., 2009). To determine whether this site
is important in ARRDC3-mediated ITGb4 internaliza-
tion, endogenous expression patterns of ITGb4, ITGb4-
pS1424 and ARRDC3 were examined using confocal
microscopy on migrating cancer cells. ARRDC3 colo-
calized with ITGb4 only on the lagging edge of the cell,
where ITGb4-pS1424 is enriched (Figure 7a). We
determined that ARRDC3 physically interacts with
ITGb4-pS1424 by endogenous coimmunoprecipitation
(Figure 7b). Densitometric analysis show approximately
70% of ITGb4-pS1424 is coimmunoprecipitated by
ARRDC3 antibody when compared with ITGb4 anti-
body. The densitometric ratio of precipitated pS1424/
ITGb4 is 3.5-fold higher for the ARRDC3 coimmuno-
precipitation when compared with the ITGb4 coimmu-
noprecipitation suggesting that ARRDC3 preferentially
interacts with this activated form of ITGb4.
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Figure 4 ARRDC3 repression promotes in vivo cell survival. Tumors were cut in half along the longest axis therefore the center-most
section of the tumor was used to make slides. Changes in necrosis are more evident when tumors of comparable size are analyzed. (a, b)
Repression of ARRDC3 (shARRDC3) leads to a decrease in xenograft tumor necrosis (outlined in black) compared with control
(shCtl), whereas overexpression of ARRDC3 (ARRDC3) leads to an increase in xenograft tumor necrosis compared with vector
control (Flag). Dashed line represents the point where two images were merged to visualize the entire tumor section. Five tumors from
each line were analyzed and the area of necrosis measured. Data bars represent mean±s.e.m. Single asterisk represents Po0.05,
whereas a double asterisk represents Po0.001 as determined by Student’s t-test. (c) ARRDC3 does not affect the number of apoptotic
cells in xenograft tumors. Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) analysis was
performed on tumor sections and the number of positive cells in 10 high-powered ﬁelds ( 40) was counted. Five tumors per group
were analyzed and data bars represent mean±s.e.m. NS, not signiﬁcant.
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Figure 5 ARRDC3 negatively regulates ITGb4. (a) Western blot analysis shows that ITGb4 protein level is affected by ARRDC3
expression. Stable alterations of ARRDC3 expression in MDA-MB-231, MDA-MB-435 and MDA-MB-435þb4 cell lines. When ARRDC3
expression was repressed using two separate short hairpin RNA constructs (shA or shC), cells showed an increase in ITGb4p r o t e i nw h e n
compared with control cells (Un or shCtl). Conversely, when cells were made to overexpress ARRDC3 (ARRDC3), ITGb4 levels decreased
when compared with vector control cells (Flag) or untransfected parental cells (Un). (b) Immunoﬂuorescence shows that when MDA-MB-
231 cells overexpress ARRDC3 using a green ﬂuorescent protein (GFP)-expressing adenovirus (adARRDC3), ITGb4 levels decrease when
compared with uninfected cells (no GFP expression) and cells infected with a control GFP-expressing adenovirus (adGFP).
Figure 6 In breast cancer cells, ARRDC3 directly interacts with ubiquitinated ITGb4 and negatively regulates protein levels in a mechanism
dependent on the proteosome. (a, b) Cells can maintain high levels of ITGb4 after ARRDC3 overexpression if treated with proteosome inhibitor
Lactacystin for 6h. (a) Western blot analysis shows that ITGb4l e v e l sa f t e rA R R D C 3o v e r e x p r e s s i o ni sr e s t o r e dw h e nt h ep r o t e o s o m ei s
inhibited. Inhibition of the proteosome is demonstrated by the accumulation of IkBa.( b) Immunoﬂuorescence demonstrates that ITGb4l e v e l s
are retained after ARRDC3 overexpression if cells are treated with proteosome inhibitor. Cells positive for adARRDC3 (green ﬂuorescent protein
(GFPþ)) are outlined with a dashed line. (c) ARRDC3 causes a complete removal of ITGb4 from the cell surface that is partially rescued with
proteosome inhibition. The cell surface of live cells were then stained with an ITGb4 antibody and analyzed by ﬂow cytometry. Uninfected GFP-
negative cells were gated out before ITGb4 levels were examined. (d) Pretreatment of MDA-MB-231 cells with proteosome inhibitor lactacystin
before the endogenous coimmunoprecipitation with antibodies against ARRDC3 and ITGb4 enriches ubiquitinated forms of ITGb4. Bands seen
in the ubiquitin immunoblots were identical in size to ITGb4 bands. Dotted line indicates noncontiguous lanes from the same ﬁlm.
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OncogeneARRDC3 speciﬁcally targets ITGb4
Cancer cells frequently have defects within vesicular
trafﬁcking and/or endocytic pathways (Mosesson et al.,
2008). To demonstrate that ARRDC3 speciﬁcally
targets ITGb4, rather than stimulating generalized
endocytosis, we examined several cell surface proteins
after cells were infected with either control or ARRDC3
over-expressing adenovirus. Analysis of nonpermeabi-
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Oncogenelized cells by ﬂow cytometry shows that ARRDC3
overexpression did not affect surface levels of ITGb1,
CD44 and EpCam (Figure 8).
Effects of ARRDC3 on in vitro tumorigenicity
is dependent on ITGb4
To determine whether ITGb4 is required to mediate the
effects of ARRDC3 on cancer cell behavior, we used
MDA-MB-435 (a cancer line which does not express
ITGb4) and MDA-MB-435þb4 cells (a daughter cell
line engineered to overexpress ITGb4), to create lines
with altered ARRDC3 levels and assayed for tumori-
genicity (Figure 5a).
Similar to MDA-MB-231 cells, the MDA-MB-
435þb4 cells showed marked changes in proliferation,
migration, invasion and anchorage independent growth.
Overexpression of ARRDC3 in MDA-MB-435þb4
cells caused decreased proliferation and migration,
whereas repression of ARRDC3 lead to increased
proliferation and migration (Supplementary Figures
S4a and b). Cell invasion assays showed a 50% decrease
in the number of invasive cells in ARRDC3 over-
expressing cells, whereas repression of ARRDC3 caused
a twofold increase (Supplementary Figure S4c). Soft
agar assays again showed that overexpression of
ARRDC3 inhibits anchorage independent growth,
whereas repressed ARRDC3 promotes in vitro tumor-
igenicity in the MDA-MB-435þb4 cells. In contrast to
the ITGb4-positive cell lines, ARRDC3 had only marginal
effects on the parental, ITGb4-negative MDA-MB-435
cell line (Supplementary Figures S4a–d). Altogether,
these data show that ARRDC3 affects in vitro tumor-
igenicity, principally in an ITGb4-dependent fashion.
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Figure 7 ARRDC3 preferentially interacts with ITGb4 when phosphorylated on serine-1494. (a) Confocal images of a migrating
MDA-MB-231 cell after wounding. Endogenous expression of ARRDC3, ITGb4 and ITGb4-pS1424 was detected. ARRDC3
colocalizes with ITGb4 on the lagging edge of the cell, where ITGb4-pS1424 is located. (b) MDA-MB-231 cells were treated with
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OncogeneARRDC3 downregulation and coordinate ITGb4
upregulation in human breast carcinogenesis and
tumor progression
As there is an extensive connection between ITGb4 and
breast carcinogenesis, we examined protein levels of
ARRDC3 and ITGb4 in normal breast tissue and
primary human breast cancers. ITGb4-positive cells
were located in the basal layer of normal ducts, whereas
ARRDC3 was more highly expressed in luminal cells (in
which ITGb4 expression is negligible) but weakly
expressed in basal cells (in which ITGb4 expression is
highest) (Figure 9b). In breast cancers, ARRDC3
expression was inversely correlated to ITGb4b y
immunoﬂuorescence and western blot (Figures 9a
and c–f).
The combination of our data and the current know-
ledge of ITGb4 strongly suggested that ARRDC3
downregulation would lead to a more aggressive or
metastatic phenotype. To analyze the expression pattern
of ARRDC3 in tumors, 52 human breast tumors of
varied grade were used for ITGb4 and ARRDC3
coimmunoﬂuorescence. Expression of ARRDC3 was
inversely correlated to tumor grade (Table 1). Within
grade 1 tumors samples, ﬁve out of six showed high
ARRDC3 staining while the outlier exhibited strong
ITGb4 staining. Interestingly, ARRDC3 expression
varied greatly in grade 2 tumors, yet levels were
inversely correlated to ITGb4 expression. Grade 3
tumors generally expressed low or undetectable levels
of ARRDC3. Although 11 out of 52 tumors samples
expressed no or low levels of ARRDC3 and ITGb4,
only 1 out of 52 tumors samples had intense staining for
both ARRCD3 and ITGb4. Overall, the data support
the hypothesis that ARRDC3 functions as a regulator of
breast cancer progression through its affects on ITGb4.
Discussion
In the present study, we describe a novel regulatory
pathway involving the internalization and degradation
of the cell surface protein ITGb4, which has signiﬁcant
effects on breast cancer cell growth and tumorigenicity.
We showed that ARRDC3, previously identiﬁed by
genetic screening as a potential tumor suppressor
(Adelaide et al., 2007), is a novel regulator of breast
cancer progression. We show that ARRDC3 directly
binds to ITGb4, speciﬁcally when phosphorylated at
S1424, ultimately leading to proteosome dependent
degradation. The subsequent change in ITGb4 protein
levels signiﬁcantly affects in vitro tumorigenic properties
such as proliferation, migration, invasion and growth in
soft agar. In vivo analyses show that ARRDC3
negatively regulates tumor growth in nude mice. In
addition, data from human breast cancer samples show
that ARRDC3 expression is inversely correlated to
ITGb4 protein levels and tumor grade.
ITGb4 is part of a genetic signature correlated to
basal-type breast cancer (Lu et al., 2008). It was
therefore very interesting to note that ARRDC3 is part
of a cluster on chromosome 5 deleted in 17% of the
same basal-type breast cancer subset (compared with
0% in luminal breast cancers) (Adelaide et al., 2007).
Seven of eight basal-like breast cancer samples we
analyzed had little to no expression of ARRDC3
(Table 1), suggesting that ARRDC3 may be down-
regulated by additional mechanisms other than chro-
mosomal deletion. We found that when ARRDC3
protein was low or absent in human breast cancers
regardless of grade or receptor status, these tumors
generally had high levels of ITGb4. We do not know the
mechanism of downregulated ARRDC3 within these
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Figure 8 The regulation of ITGb4 by ARRDC3 is speciﬁc and not
a product of generalized increased endocytosis. MDA-MB-231 cells
were infected with either a green ﬂuorescent protein (GFP)-
expressing adenovirus (þGFP) or an ARRDC3-expressing adeno-
virus (þARRDC3). Nonpermeabilized cells were then analyzed by
ﬂow cytometry for various cell surface proteins. ARRDC3 over-
expression did not affect surface levels of ITGb1, CD44 or EpCam.
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OncogeneFigure 9 Expression of ARRDC3 in human breast tumors. (a) Western blot analysis of protein extracts from primary human breast
tumors (invasive ductal carcinomas). ARRDC3 and ITGb4 expression are inversely correlated. (b–f) Immunoﬂuorescence of primary
breast or breast tumor tissue demonstrated an inverse correlation to ARRDC3 and ITGb4 protein levels. (b) ARRDC3 is primarily
expressed in the luminal cells in normal breast tissue. (c) Grade 1 breast tumors tend to express high levels of ARRDC3 and low levels
of ITGb4. (d) Grade 2 human breast tumors showed varied expression levels of ARRDC3. Expression is always the inverse of ITGb4
expression. (e) Grade 3 breast tumors tend to express low or undetectable levels of ARRDC3 and high levels of ITGb4. (f) Basal breast
cancers with high ITGb4 expression express very low or no levels of ARRDC3.
Table 1 Expression of ARRDC3 in human breast tumors
ID HER2 ER PR Cancer type Grade ITGb4 ARRDC3
0630T  þ Weak Lobular carcinoma 1 þ þþþ
0832T  þ   Ductal carcinoma 1 þ þþþ
0885T  þ þ Ductal carcinoma 1 þþ þ
0909T  þ Weak Ductal carcinoma 1   þþþ
1334T  þ þ Lobular carcinoma 1 þþþ þ
1640T  þ   Ductal carcinoma 1 þþ þþ
0199T þþ þ Ductal carcinoma 2 þþ þþ
0248T  þ þ Ductal carcinoma 2 þþþ þ
0327T þþ þ Ductal carcinoma 2 þþ þþ
0424T  þ þ Papillary carcinoma 2  þ
0448T      Ductal carcinoma 2 þþþ þ
0462T  þ   Ductal carcinoma 2 þþ þþ
0480T  þ þ Ductal carcinoma 2 þþ
0545T þþ   Ductal carcinoma 2 þþ þþ
0576T  þ   Ductal carcinoma 2 þþþ þ
0638T  þ   Ductal carcinoma 2 þþ þ
0837T Weak/     Ductal carcinoma 2 þþ þ
0884T  þ   Lobular carcinoma 2 þþ þ
0934T þ    Ductal carcinoma in situ 2 þþþ þ
0960T þþ þ Ductal carcinoma 2 þþ
1003T  þ þ Ductal carcinoma 2  þ þ
1099T  þ   Ductal carcinoma 2 þþ
1281T  þ þ Lobular carcinoma 2 þþ  
1376T  þ þ Lobular carcinoma 2 þþþ þ
1403T þþ þ Ductal carcinoma 2 þþ þþ
1404T  þ þ Lobular carcinoma 2 þþþ þ
1471L  þ þ Carcinoma 2 þþþ þ
1471T  þ þ Ductal carcinoma 2 þþþ þ
1502T  þ þ Ductal carcinoma 2 þþ þþ
1569T  þ þ Ductal carcinoma 2 þ þþþ
0237T þ    Ductal carcinoma 3 þþþ  
0316T þ  þ Ductal carcinoma 3 þþþ þ
0442T þ    Ductal carcinoma 3 þþþ þ
0454T  þ þ Lobular carcinoma 3 þþþ þþ
0471T þþ   Lobular carcinoma 3  þ
0489T  þ þ Lobular carcinoma 3 þ 
0577T  þ   Lobular carcinoma 3 þþþ þ
0690T      Ductal carcinoma 3  þ
0738T    þ Ductal carcinoma 3 þþþ þ
0839T      Ductal carcinoma 3   
0902T      Ductal carcinoma 3  þ þ
0957T      Ductal carcinoma 3 þþþ þ
0959M  þ   Carcinoma 3  þ
0959T  þ   Ductal carcinoma 3 þþ
1060T  þ   Ductal carcinoma 3 þþ
1097T Weak þ Weak Ductal carcinoma 3 þþ þ
1200T      Ductal carcinoma 3 þþþ  
1342M      Ductal carcinoma 3 þþþ þ
1550T  þ þ Lobular carcinoma 3 þþþ þ
1623T  þ þ Ductal carcinoma 3 þþþ þ
1645T NR þþ Lobular carcinoma 3 þþ  
1659T  þ   Ductal carcinoma 3 þþþ þ
Abbreviations:  , indicates no detectable expression; þ, is low expression; þþ, is moderate expression; þþþ, is high expression; ER, estrogen
receptor; HER2, human epidermal growth factor receptor 2; ITGb4, integrin b4; NR, not reported; PR, progesterone receptor.
A table of the 52 human breast tumors analyzed for ARRDC3 and ITGb4 expression using immunoﬂuorescence. ID refers to the UMass Tissue
Bank tumor number. HER2, ER and PR statuses, cancer type and grade are those determined at the time of diagnosis. All samples were processed
at the same time using the same master-mix of primary and secondary antibodies. Images from each sample were taken all on the same day using
the same exposure times for each channel. Expression levels were scored by a pathologist (SL) blinded to the sample information.
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Oncogenetumors, however chromosome deletion is likely not the
only cause of ARRDC3 defects. Further genetic,
epigenetic and mutational analyses of the ARRDC3
locus are needed to more fully investigate the transcrip-
tional regulation of ARRCD3 within tumors.
Interestingly, some tumors we evaluated maintained
expression of both ARRDC3 and ITGb4. It is possible
that the effects of ARRDC3 on ITGb4 are simply dose
dependent and moderate expression of ARRDC3
maintains intermediate levels of ITGb4. Low or
moderate levels of ARRDC3 may also allow for the
recycling of ITGb4 similar to the effects of b-arrestin on
GPCRs (Luttrell and Lefkowitz, 2002). The presence of
increased surface ITGb4 we observed after treatment
with a proteosome inhibitor may be evidence of such a
mechanism (Figure 5c). This would facilitate the speed
in which ﬁlamentous actin protrusions form, thus
promoting tumor progression. However, further traf-
ﬁcking studies are necessary to determine whether
ITGb4 is actively being recycled to the cell surface in
the absence of degradation.
Until recently, there have been relatively few investi-
gations of the factors involved in ITG endocytosis.
Internalization of ITGs a5b1, avb6, avb3, a6b1h a v e
been associated with clathrin-mediated endocytosis
(Caswell and Norman, 2008; Ezratty et al., 2009),
whereas ITGs a5b1, avb3, a2b1 (Caswell and Norman,
2008; Shi and Sottile, 2008) have been connected to
caveolae dependent endocytosis. ITGa6b4 has been
shown to be associated with lipid rafts (Gagnoux-
Palacios et al., 2003) suggesting that caveolae may have
a role in localization. However, not all ITGa6b4 was
found associated with lipid rafts. Our data provides
additional insight to the area of ITG endocytosis.
As ARRDC3 contains clathrin-binding motifs, it is
possible that it functions within a clathrin-dependent
mechanism although further investigation of the protein
complexes within this pathway is needed. Lastly,
ARRDC3 does not seem to affect b1IGTs (Figure 8),
and because of the unique long cytoplasmic tail of
ITGb4, ARRDC3 is likely speciﬁc for this IGT.
It has been hypothesized that during the progression
from normal epithelium to invasive carcinoma, the
function of ITGb4 switches from a mechanical adhesive
device into a signaling-competent receptor. In this case,
ITGb4 needs to be liberated from hemidesmosome
where it can then be trafﬁcked to actin-rich motility
structures (ﬁlopodia and lamellae) (Mercurio et al.,
2001; Santoro et al., 2003; Lipscomb and Mercurio,
2005). Our ﬁndings highlight the importance of the
ITGb4-pS1424 site in this process as endogenous
ARRDC3 colocalizes with this phosphorylated form
of ITGb4, likely during hemidesmosome disassembly
and ITGb4 internalization. The classic arrestin family
member b-arrestin 1 is known to down-regulate
G-protein mediated signaling, initiate internalization
from the membrane and mediate additional signaling
cascades (Claing et al., 2002). b-Arrestin 2 has been
shown to have a similar role in controlling the single
transmembrane receptor, transforming growth factor-b-
R III (Chen et al., 2003). In addition, there is emerging
evidence suggesting a role for b-arrestins in cancer
(Buchanan et al., 2006; Raghuwanshi et al., 2008; Li
et al., 2009). It is clear from our data that ARRDC3 has
a role in the regulation of ITGb4 protein levels and
likely contributes to the control of ITGb4 function
during breast cancer progression.
Our data does not exclude the possibility that
ARRDC3 has an ITGb4 independent mechanism of
action in cancer cells or in normal cells. The effects
of ARRDC3 on cancer cells lacking ITGb4 had
marginal statistical signiﬁcance and the overall effects
were small (Supplementary Figures S2a–d). It is there-
fore unclear whether these effects are biologically
signiﬁcant. Considering its similarity to b-arrestins,
ARRDC3 may also regulate GPCRs. Possible targets
could include smoothened and frizzled receptors (class-6
GPCRs) or RhoA/C (class-1 GPCRs); which also have
extensive implications in cancer.
In summary, our data identiﬁes ARRDC3 as a novel
regulator of breast cancer growth and progression that
targets ITGb4 for internalization and proteosome
dependent degradation. We reveal several oncogenic
properties affected by changes in ARRDC3 expression
and identify a correlation between ARRDC3 expression
and human breast tumor grade or aggressiveness. Our
data also open several potential avenues of future
research to better understand the potential signiﬁcance
of this novel regulatory pathway in carcinogenesis.
Materials and methods
Cells and reagents
MDA-MB-435 cancer cells expressing wild-type ITGb4 were
generated previously (Shaw et al., 1997). MDA-MB-231 breast
carcinoma cells were obtained from the Lombardi Breast
Cancer Depository (Georgetown University). The following
antibodies were used: rabbit pAb 505 (ITGb4-speciﬁc, gift
from Dr Arthur Mercurio, UMass Medical School, Worcester,
MA, USA); rat mAb 439-9B (ITGb4-speciﬁc, BD Biosciences,
San Jose, MA, USA); rabbit pAb S1424 (ITGb4 phospho-
serine 1424 speciﬁc, gift from Dr Isaac Rabinovitz, BIDMC,
Boston, MA, USA); rabbit pAb ARRDC3 (Abcam, Cam-
bridge, MA, USA); and mouse mAb Arrdc3 generated in our
laboratory.
Cloning and generation of stable lines
pSuper vectors (oligoengine) containing control short hairpin
RNA (shCtl target sequence: TTCTCCGAACGTGTCA
CGT) and short hairpin RNAs targeting ARRDC3 (target
sequence A:GGCCTTGGCTACTACCAGT; target sequence
C: GCGTGGAATATTCACTAAT) were generated in our lab
per manufacturers recommended protocol. Full-length human
ARRDC3 cDNA and Flag-LacZ fusion cDNA were cloned
into the pBABE-puro expression vector (Addgene, Cambridge,
MA, USA). Cells were transfected with Fugene HD (Roche
Applied Science, Indianapolis, IN, USA) following manufac-
turer’s protocol. Stable transformants were selected using
puromycin and pooled.
Adenoviral preparation
Full-length human ARRDC3 cDNA was initially cloned into
pLE green ﬂuorescent protein (Clontech, Mountain View, CA,
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protein was then cloned into Adeno-X LP CMV using the
Adeno-X Expression System 2 kit (Clontech). Adeno-X maxi
puriﬁcation kit (Clontech) was used to purify the adenovirus.
For all steps, the manufacturer’s protocol was followed. The
amount of virus needed for each cell type was determined
empirically.
Immunoﬂuorescence
Cells cultured on coverslips or frozen sections of O.C.T.-ﬁxed
human breast cancer tissue (obtained from the UMass Cancer
Center Tumor Bank with IRB approval #13176) were ﬁxed
with acetone and permeabilized by incubating with phosphate-
buffered salineþTriton and blocked with 5% goat serum
(Gibco, Carlsbad, CA, USA). Slides were incubated with
primary antibody (rabbit polyclonal ARRDC3 (Abcam,
Cambridge, MA, USA) and/or ITGb4 439-9b (BD-Pharmin-
gen, San Jose, CA, USA)) for 2h at room temperature or
overnight at 41C. After washing, slides were incubated with
secondary antibodies conjugated with either ﬂuorescein
isothiocyanate or Texas-Red (Vector Laboratories, Burlin-
game, CA, USA) for 2h (room temp). Slides were mounted
using Vectashield with 40-6-diamidino-2-phenylindole (Vector
Laboratories) and were analyzed using a ﬂuorescence micro-
scope.
Wound assay
In all, 5 10
5 cells were evenly plated in a six-well plate. At
24h after plating, conﬂuent cells were treated with 15mg/ml
mitomycin C (Roche Applied Science) for 90min at 371C. The
monolayer was scratched with a P200 pipette tip and washed
three times to remove ﬂoating cells. The wound closure was
then monitored by digital photography.
Growth in soft agar
In all, 1.0 10
3 cells were suspended in 2ml of serum-
containing medium containing 0.3% agar and overlaid on a
1ml base layer of 0.75% agar in six-well plates. The soft agar
was overlaid with complete medium (0.5ml per well), which
was changed every 2 days. After 3–4 weeks of incubation,
viable colonies were stained by adding 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide into the covering media.
Images were captured using bright-ﬁeld microscopy and the
number and size of the colonies were analyzed using ImageJ
software. Only colonies with a diameter of 450mm were
counted.
Invasion
Matrigel invasion assays were carried out as described
previously using 6.5-mm Transwell chambers (8-mm pore size,
CoStar, St Louis, MO, USA) (Shaw et al., 1997). After 4h,
the cells that had invaded to the lower surface of the ﬁlters
were ﬁxed in methanol for 10min. Filters were mounted on
glass slides using Vectashield mounting medium containing
40-6-diamidino-2-phenylindole (Vector Laboratories). Invasion
was quantiﬁed by counting the number of stained nuclei in
ﬁve independent ﬁelds in each transwell using ImageJ
software.
Xenograft mouse studies
Animals’ care was in accordance with guidelines approved by
IACUC. Cells were trypsinized, washed with sterile phosphate-
buffered saline and resuspended in 35ml phenol red-free
Matrigel immediately before injection. Old female immuno-
compromised mice (9 weeks) (nu/nu; National Cancer In-
stitute) were anesthetized brieﬂy with isoﬂuorane and cells
were injected into the #3 and #8 mammary fat pad (1 10
6
cells per injection, two injection sites per mouse). Tumor
volume was determined using the following formula: (4/3)p(1/
2 smaller diameter)
2 (1/2 larger diameter). Final dissected
tumor volume was determined using the following formula: (4/3)
p(1/2 length)(1/2 width)(1/2 height). Percent tumor ne-
crosis was determined by outlining the necrotic area in the area
ﬁnder function of ImageJ and dividing it by the total area of
the tumor.
Immunoprecipitation
Cells were treated for 3–4h with 1mM sodium orthovanadate
or 1mM NaF or 50mM Lactacystin and solubilized at 41C for
15min in NP-40 Lysis buffer supplemented with 1mm sodium
orthovanadate, 1mm NaF and protease inhibitors (Complete
mini tab; Roche Applied Science). Aliquots of cell extracts
containing equivalent protein amounts were incubated over-
night at 41C with antibodies and protein-A/G-Sepharose
(Santa Cruz, Santa Cruz, CA, USA) with constant agitation.
Immune complexes and aliquots of cell extracts containing
equivalent total protein amounts were then analyzed by
western blot.
Western blot analysis
Cell extracts containing equivalent protein amounts were
resolved by sodium dodecyl sulfate–polyacrylamide gel and
were transferred to nitrocellulose membranes. Membranes
were blocked for an hour using a 50mM Tris buffer (pH 7.5)
containing 0.15mM NaCl and 0.05% Tween 20 and 5% (w/v)
Blocker (BioRad, Hercules, CA, USA) in phosphate-buffered
salineþ Tween 20. Membranes were incubated overnight at
41C in the same buffer containing primary antibodies. Proteins
were detected by enhanced chemiluminescence (Pierce, Rock-
ford, IL, USA). For phospho-immunoblots, the blocking
buffer for the primary antibodies contained 5% (w/v) bovine
serum albumin.
Statistical analysis
All values in the present study were expressed as mean±s.e.m.
unless otherwise noted. The signiﬁcant differences between the
groups were analyzed by a Student’s t-test and a P-value of
o0.05 was considered signiﬁcant.
Abbreviations
EpCam, epithelial cell adhesion molecule; ER, estrogen
receptor; GPCRs, G-protein coupled receptors; HD, hemi-
desmosomes; ITGb1, integrin b1; ITGb4, integrin b4; PKC,
protein kinase C; PR, progesterone receptor; OCT, optimal
cutting temperature compound.
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